Haematopoietic stem cell transplantation as first-line treatment in myeloma: a global perspective of current concepts and future possibilities by Catriona Elizabeth Mactier, Md Serajul Islam

“…Consolidation and maintenance chemotherapies, particularly thalidomide and bortezomib, aim to improve and prolong disease response to transplantation and delay recurrence. …”
Get full text

Survival outcomes among patients with multiple myeloma in the era of novel agents: exploratory assessment using an electronic medical record database in Japan by Shuji Uno, Shuichi Midorikawa, Kei Inoue, Daisuke Ichikawa, Tomoki Ito, Junya Kuroda, Kenshi Suzuki

“…We extracted EMRs in the Real World Data (RWD) database of patients with a confirmed diagnosis of MM and treatment history with bortezomib, thalidomide, and/or lenalidomide. OS and prognostic factors for OS were analyzed using a univariate analysis and decision tree model. …”
Get full text

Evaluation of Novel Fetal Hemoglobin Inducer Drugs in Treatment of β-Hemoglobinopathy Disorders by Ali Dehghani Fard, Seyed Ahmad Hosseini, Mohammad Shahjahani, Fatemeh Salari, Kaveh Jaseb

“…HbF inducers including hydroxyurea, histone deacetylase (HDAC) inhibitor agents such as sodium butyrate, azacitidine, decitabine and new immunomodulator drugs like pomalidomide, lenalidomide and thalidomide can reduce α-globin chain production in erythroid progenitors and improve α: β chain imbalance, the most crucial complication of β-thalassemia. …”
Get full text

Systemic Juvenile Idiopathic Arthritis/Pediatric Still’s Disease, a Syndrome but Several Clinical Forms: Recent Therapeutic Approaches by Pierre Quartier

“…Results: A few situations deserve particular attention: 1/patients with recent-onset SJIA who may benefit from a treat-to-target approach with a key place for interleukin (IL)-1 inhibition; 2/SJIA patients refractory to Il-1 and IL-6 antagonists in whom several options may be discussed, including thalidomide or allogeneic hematopoietic stem cell transplantation; 3/SJIA patients with macrophage activation syndrome who may benefit from both well-used classical treatment and innovative approaches, such as anti-interferon gamma therapy or Janus Kinase (JAK) inhibitors; 4/SJIA with severe lung involvement, 5/SJIA patients who achieve complete remission on treatment, with some recent evidence that treatment may be reduced in intensity but not so easily withdrawn. …”
Get full text

Extramedullary relapse of Immunoglobulin A-kappa myeloma manifesting as plasmacytoma of the pleura without bone marrow involvement and following autologous bone marrow transplant:... by Alireza Rezvani, Reza Shahriarirad, Mohammad Javad Fallahi, Ali Zeighami

“…The patient was effectively treated with dexamethasone, thalidomide, cisplatin, doxorubicin, cyclophosphamide, and etoposide with no notable adverse effects. …”
Get full text

Direct-to-biology, automated, nano-scale synthesis, and phenotypic screening-enabled E3 ligase modulator discovery by Zefeng Wang, Shabnam Shaabani, Xiang Gao, Yuen Lam Dora Ng, Valeriia Sapozhnikova, Philipp Mertins, Jan Krönke, Alexander Dömling

“…Abstract Thalidomide and its analogs are molecular glues (MGs) that lead to targeted ubiquitination and degradation of key cancer proteins via the cereblon (CRBN) E3 ligase. …”
Get full text

Case report: Relapsed/refractory extranodal natural killer/T-cell lymphoma nasal type with extensive central nervous system involvement by Austėja Dapkevičiūtė-Purlienė, Vytautas Augustinavičius, Andrius Žučenka

“…Overall, the patient received nine treatment lines, including chemotherapy, craniospinal irradiation, allogeneic stem cell transplant (alloSCT), donor lymphocyte infusions, and novel agents (Nivolumab, Daratumumab, Thalidomide, Lenalidomide, virus-specific T cells) combined with intrathecal chemotherapy. …”
Get full text

The age-dependent changes in risk weights of the prognostic factors for multiple myeloma by Chenxing Du, Lingna Li, Huishou Fan, Xuehan Mao, Jiahui Liu, Yan Xu, Weiwei Sui, Shuhui Deng, Chengwen Li, Jiawei Zhao, Shuhua Yi, Mu Hao, Dehui Zou, Yaozhong Zhao, Lugui Qiu, Gang An

“…Patients received bortezomib or thalidomide-based induction and maintenance therapy. …”
Get full text

Lenalidomide or bortezomib as maintenance treatment remedy the inferior impact of high-risk cytogenetic abnormalities in non-transplant patients with newly diagnosed multiple myelo... by Zhe Zhuang, Ying Tian, Lei Shi, Dongmei Zou, Ru Feng, Wei-wei Tian, Hong Yu, Fei Dong, Aijun Liao, Yanping Ma, Qinhua Liu, Shuangjiao Liu, Hongmei Jing, Rong Fu, Liang-ming Ma, Hui Liu, Wanling Sun, Li Bao, Yin Wu, Wenming Chen, Junling Zhuang

“…In this real-world multi-centered study, our findings suggest that clinicians prefer to prescribe lenalidomide or bortezomib as maintenance therapy in high-risk settings, which are superior to thalidomide in non-transplant MM patients. Achievement of CR and maintenance duration over 2 years are positive factors that influence survival.…”
Get full text

Patients Age 40 Years and Younger With Multiple Myeloma Have the Same Prognosis as Older Patients: An Analysis of Real-World Patients' Evidence From Latin America by Humberto Martínez-Cordero, Camila Peña, Natalia Paola Schutz, Virginia Bove, Fiorella Villano, Cecilia Beltran, Javiera Donoso, Hernán López-Vidal, Macarena Alejandra Roa Salinas, Pablo Soto, Paola Ochoa, Patricio Duarte, Guillermina Remaggi, Ariel Corzo, Claudia Shanley, Sergio Lopresti, Sergio Orlando, Verónica Verri, Luis Darío Quiroga, Dorotea Fantl, Jhoanna Ramirez, Alejandro Ospina-Idárraga, Henry Idrobo, Guillermo Quintero, Rigoberto Gomez, Omar Cantú-Martínez, David Gomez-Almaguer, Guillermo J. Ruiz-Arguelles, Kenny Mauricio Galvez-Cárdenas, Luis Antonio Salazar, Isabella Novoa-Caicedo, María Cynthia Fuentes-Lacouture, Paola Spirko, María Isabel Arbeláez, Mario Pereira, Jaime Valdes, Jule Vasquez, Alana von Glasenapp, Eloísa Riva

“…The most used regimen in young patients was cyclophosphamide, bortezomib, dexamethasone, followed by cyclophosphamide, thalidomide, dexamethasone and bortezomib, thalidomide, dexamethasone. …”
Get full text

REAL-WORLD TREATMENT PATTERNS AND OUTCOMES IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WITH AT LEAST ONE PRIOR THERAPY IN BRAZIL by A Maiolino, M Capra, PL Lin, T Rajput, HS Friedman, C Tekle, P Bueno, E Carmo, A Freitas, F Magro

“…LEN and thalidomide-based regimens (37.7% each) were used as maintenance therapy in 1L. …”
Get full text

Herbal Medicines—Are They Effective and Safe during Pregnancy? by Beata Sarecka-Hujar, Beata Szulc-Musioł

“…Since the teratogenicity of Thalidomide has been proven, herbal products are more commonly used in pregnancy to not only relieve morning sickness but also to fight infections. …”
Get full text

The Use of Oncolytic Viruses in the Treatment of Multiple Myeloma by Georgia Stewart, Andrew Chantry, Michelle Lawson

“…Current anti-myeloma therapies (conventional chemotherapies, immunomodulatory drugs i.e., thalidomide and its’ analogues, proteasome inhibitors, monoclonal antibodies, and radiotherapy) initially substantially debulk tumour burden, but after a period of remission ‘plateau phase’ disease invariably relapses due to tumour recrudescence from foci of minimal residual disease (MRD) and accumulating drug resistance. …”
Get full text

Pomalidomide-induced hypothyroidism by Sulaiman Haji Ali, K Aljenaee, W A Wan Mahmood, M Hatunic

“…Hypothyroidism is a recognized side effect of thalidomide drugs. We herein report a case of 83-year-old Irish female with a diagnosis of multiple myeloma and a background history of type 2 diabetes mellitus and hypertension. …”
Get full text

Pharmacovigilance in High-Income Countries: Current Developments and a Review of Literature by Muhammad Akhtar Abbas Khan, Saima Hamid, Zaheer-Ud-Din Babar

“…All ten pioneering members of the Uppsala monitoring centre are from high-income countries and were the first responders after the thalidomide tragedy by making drug evaluation committees, introducing the ADR reporting forms and taking safety measures. …”
Get full text

Survival outcomes among patients with multiple myeloma in the era of novel agents: exploratory assessment using an electronic medical record database in Japan. by Shuji Uno, Shuichi Midorikawa, Kei Inoue, Daisuke Ichikawa, Tomoki Ito, Junya Kuroda, Kenshi Suzuki

“…We extracted EMRs in the Real World Data (RWD) database of patients with a confirmed diagnosis of MM and treatment history with bortezomib, thalidomide, and/or lenalidomide. OS and prognostic factors for OS were analyzed using a univariate analysis and decision tree model. …”
Get full text

Lenalidomide in Multiple Myeloma: Review of Resistance Mechanisms, Current Treatment Strategies and Future Perspectives by Piotr Kulig, Sławomir Milczarek, Estera Bakinowska, Laura Szalewska, Bartłomiej Baumert, Bogusław Machaliński

“…The first molecule belonging to the IMiDs was thalidomide. Subsequently, its novel derivatives, lenalidomide (LEN) and pomalidomide (POM), were implemented. …”
Get full text

Treatment of Behcet’s disease by Fereydoun Davatchi, Nasrin Moghimi, Mohammad Mousavi, Alimohammad Fatemi

“…In refractory cases, levamisole, thalidomide, and dapsone may be of help. For major organ involvement like the eyes and the brain, immunosuppressive drugs and prednisolone are the gold standard. …”
Get full text

QSPR/QSAR analysis of some eccentricity based topological descriptors of antiviral drugs used in COVID-19 treatment via Dε- polynomials by Deepalakshmi Sarkarai, Kalyani Desikan

“…Antiviral medications, such as Arbidol, Chloroquine, Hydroxy-Chloroquine, Lopinavir, Remdesivir, Ritonavir, Thalidomide and Theaflavin, are often used to treat COVID-19. …”
Get full text

Successful treatment of a refractory intestinal Behcet’s disease with an oncology history by Vedolizumab: a case report and literature review by Ruixia Li, Xiaofei Li, He Zhou, Yanting Shi, Fang Wang, Tong Wu, Jie Liang

“…However, her oral and vulvar ulcers remained unresolved, which disappeared after adding thalidomide.ConclusionVDZ may be a safe and effective option for refractory intestinal BD patients who do not respond well to conventional treatments, especially those with an oncology history.…”
Get full text